Experienced in Chondrosarcoma

Dr. Priya U. Kumthekar

Hematology Oncology | Neurology | Hematology
Northwestern Medical Group
675 N St Clair St Ste 20-100, Galter Pavilion, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
19 Years of Experience
Experienced in Chondrosarcoma
Northwestern Medical Group
675 N St Clair St Ste 20-100, Galter Pavilion, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Priya Kumthekar is a Hematologist Oncology specialist and a Neurologist in Chicago, Illinois. Dr. Kumthekar has been practicing medicine for over 19 years and is rated as an Experienced provider by MediFind in the treatment of Chondrosarcoma. Her top areas of expertise are Astrocytoma, Glioblastoma, Brain Tumor, and Glioma.

Her clinical research consists of co-authoring 114 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Northeast Ohio Medical University College Of Medicine, 2007.0
Residency
McGaw Medical Center of Northwestern University
Specialties
Hematology Oncology
Neurology
Hematology
Licenses
Psychiatry & Neurology in IL
Board Certifications
American Board Of Psychiatry And Neurology - Neurology (Certified)
Hospital Affiliations
Northwestern Memorial Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

675 N St Clair St Ste 20-100, Galter Pavilion, Chicago, IL 60611
Call: 312-695-4360

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: December 12, 2025
Intervention Type: Drug
Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib
Study Phase: Phase 2
Genomically-Guided Treatment Trial in Brain Metastases
Genomically-Guided Treatment Trial in Brain Metastases
Enrollment Status: Suspended
Publish Date: December 12, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Paxalisib, Entrectinib
Study Phase: Phase 2
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: October 31, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Phase 1 / 2 Trial of Blood-brain Barrier Opening With an Implantable Ultrasound Device SonoCloud-9 and Treatment With Albumin-bound Paclitaxel and Carboplatin in Patients With Recurrent Glioblastoma
Phase 1 / 2 Trial of Blood-brain Barrier Opening With an Implantable Ultrasound Device SonoCloud-9 and Treatment With Albumin-bound Paclitaxel and Carboplatin in Patients With Recurrent Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2025
Intervention Type: Drug, Device
Study Drug: Chemotherapy, Albumin-Bound Paclitaxel
Study Phase: Phase 1/Phase 2
A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Subjects With Recurrent or Progressive Glioblastoma or Grade III Malignant Glioma
A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Subjects With Recurrent or Progressive Glioblastoma or Grade III Malignant Glioma
Enrollment Status: Completed
Publish Date: April 16, 2025
Intervention Type: Drug, Biological
Study Drugs: Ad-RTS-hIL-12, Veledimex
Study Phase: Phase 1
A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884) in Subjects With Advanced or Refractory Cancer and in Subjects Who Have Progressed During Treatment With a PD-1/PD-L1 Inhibitor as Their Most Recent Therapy
A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884) in Subjects With Advanced or Refractory Cancer and in Subjects Who Have Progressed During Treatment With a PD-1/PD-L1 Inhibitor as Their Most Recent Therapy
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
Enrollment Status: Terminated
Publish Date: December 16, 2024
Intervention Type: Drug, Device, Radiation
Study Drugs: Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Bevacizumab, Carmustine
Study Phase: Phase 1/Phase 2
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: August 02, 2024
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
Enrollment Status: Completed
Publish Date: May 11, 2023
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Depatuxizumab
Study Phase: Phase 3
A Phase 0 First-In-Human Study Using NU-0129: A Spherical Nucleic Acid (SNA) Gold Nanoparticle Targeting BCL2L12 in Recurrent Glioblastoma Multiforme or Gliosarcoma Patients
A Phase 0 First-In-Human Study Using NU-0129: A Spherical Nucleic Acid (SNA) Gold Nanoparticle Targeting BCL2L12 in Recurrent Glioblastoma Multiforme or Gliosarcoma Patients
Enrollment Status: Completed
Publish Date: August 26, 2022
Intervention Type: Other, Drug
Study Phase: Early Phase 1
A Phase II, Open Label, Clinical Trial Of Pre-Surgical and Adjuvant Treatment of Recurrent Malignant Glioma With Tremelimumab and Durvalumab (MEDI4736) Alone and in Combination to Determine Immunologic Changes From Treatment
A Phase II, Open Label, Clinical Trial Of Pre-Surgical and Adjuvant Treatment of Recurrent Malignant Glioma With Tremelimumab and Durvalumab (MEDI4736) Alone and in Combination to Determine Immunologic Changes From Treatment
Enrollment Status: Completed
Publish Date: April 18, 2022
Intervention Type: Biological, Procedure, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Enrollment Status: Completed
Publish Date: July 15, 2021
Intervention Type: Biological
Study Drugs: DNX-2401 Adeno-Associated Oncolytic Virus Delta-24 Vaccine, Pembrolizumab
Study Phase: Phase 2
A Phase II Trial of Bevacizumab in Patients With Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy
A Phase II Trial of Bevacizumab in Patients With Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy
Enrollment Status: Completed
Publish Date: September 17, 2019
Intervention Type: Procedure, Biological
Study Phase: Phase 2
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: October 23, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 16 Less Clinical Trials

114 Total Publications

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 01, 2025
View All 114 Publications
Similar Doctors
Distinguished in Chondrosarcoma
Dr. Marta Batus
Oncology
Distinguished in Chondrosarcoma
Dr. Marta Batus
Oncology

Rush University Medical Group

1620 W Harrison St, 
Chicago, IL 
 (3.2 miles away)
Languages Spoken:
English, Polish, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Marta Batus is an Oncologist in Chicago, Illinois. Dr. Batus is rated as an Elite provider by MediFind in the treatment of Chondrosarcoma. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Adult Soft Tissue Sarcoma, and Small Cell Lung Cancer (SCLC). Dr. Batus is currently accepting new patients.

Advanced in Chondrosarcoma
Dr. Samir D. Undevia
Hematology | Oncology
Advanced in Chondrosarcoma
Dr. Samir D. Undevia
Hematology | Oncology

Endeavor Health Medical Group

801 S Washington St, Fl 3, 
Naperville, IL 
 (29.4 miles away)
630-527-5359
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Samir Undevia is a Hematologist and an Oncologist in Naperville, Illinois. Dr. Undevia is rated as a Distinguished provider by MediFind in the treatment of Chondrosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Myxoid Liposarcoma, and Epithelioid Sarcoma. Dr. Undevia is currently accepting new patients.

Advanced in Chondrosarcoma
Dr. Syed N. Haider
Hematology Oncology | Hematology | Oncology
Advanced in Chondrosarcoma
Dr. Syed N. Haider
Hematology Oncology | Hematology | Oncology

Froedtert South Inc

9555 76th St, 
Pleasant Prairie, WI 
 (48.8 miles away)
262-577-8300
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Syed Haider is a Hematologist Oncology specialist and a Hematologist in Pleasant Prairie, Wisconsin. Dr. Haider is rated as a Distinguished provider by MediFind in the treatment of Chondrosarcoma. His top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, and Paget Disease of the Breast. Dr. Haider is currently accepting new patients.

VIEW MORE CHONDROSARCOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kumthekar's expertise for a condition
ConditionClose
  • Elite
  • Astrocytoma
    Dr. Kumthekar is
    Elite
    . Learn about Astrocytoma.
    See more Astrocytoma experts
  • Brain Tumor
    Dr. Kumthekar is
    Elite
    . Learn about Brain Tumor.
    See more Brain Tumor experts
  • Glioblastoma
    Dr. Kumthekar is
    Elite
    . Learn about Glioblastoma.
    See more Glioblastoma experts
  • Glioma
    Dr. Kumthekar is
    Elite
    . Learn about Glioma.
    See more Glioma experts
  • Gliomatosis Cerebri
    Dr. Kumthekar is
    Elite
    . Learn about Gliomatosis Cerebri.
    See more Gliomatosis Cerebri experts
  • Distinguished
  • Atypical Teratoid Rhabdoid Tumor (ATRT)
    Dr. Kumthekar is
    Distinguished
    . Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
    See more Atypical Teratoid Rhabdoid Tumor (ATRT) experts
  • Embryonal Tumor with Multilayered Rosettes
    Dr. Kumthekar is
    Distinguished
    . Learn about Embryonal Tumor with Multilayered Rosettes.
    See more Embryonal Tumor with Multilayered Rosettes experts
  • Ependymoma
    Dr. Kumthekar is
    Distinguished
    . Learn about Ependymoma.
    See more Ependymoma experts
  • Gliosarcoma
    Dr. Kumthekar is
    Distinguished
    . Learn about Gliosarcoma.
    See more Gliosarcoma experts
  • Meningioma
    Dr. Kumthekar is
    Distinguished
    . Learn about Meningioma.
    See more Meningioma experts
  • Metastatic Brain Tumor
    Dr. Kumthekar is
    Distinguished
    . Learn about Metastatic Brain Tumor.
    See more Metastatic Brain Tumor experts
View All 11 Distinguished Conditions
  • Advanced
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Kumthekar is
    Advanced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • Breast Cancer
    Dr. Kumthekar is
    Advanced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Craniopharyngioma
    Dr. Kumthekar is
    Advanced
    . Learn about Craniopharyngioma.
    See more Craniopharyngioma experts
  • HER-2 Positive Breast Cancer
    Dr. Kumthekar is
    Advanced
    . Learn about HER-2 Positive Breast Cancer.
    See more HER-2 Positive Breast Cancer experts
  • Lung Adenocarcinoma
    Dr. Kumthekar is
    Advanced
    . Learn about Lung Adenocarcinoma.
    See more Lung Adenocarcinoma experts
  • Medulloblastoma
    Dr. Kumthekar is
    Advanced
    . Learn about Medulloblastoma.
    See more Medulloblastoma experts
View All 10 Advanced Conditions
  • Experienced
  • Acoustic Neuroma
    Dr. Kumthekar is
    Experienced
    . Learn about Acoustic Neuroma.
    See more Acoustic Neuroma experts
  • Adult Soft Tissue Sarcoma
    Dr. Kumthekar is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Alveolar Soft Part Sarcoma
    Dr. Kumthekar is
    Experienced
    . Learn about Alveolar Soft Part Sarcoma.
    See more Alveolar Soft Part Sarcoma experts
  • Arachnoiditis
    Dr. Kumthekar is
    Experienced
    . Learn about Arachnoiditis.
    See more Arachnoiditis experts
  • Bone Tumor
    Dr. Kumthekar is
    Experienced
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Brain Stem Cancer
    Dr. Kumthekar is
    Experienced
    . Learn about Brain Stem Cancer.
    See more Brain Stem Cancer experts
View All 47 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.